FREE STANDARD SHIPPING ON ORDERS $250+

ARA-290

Shop

ARA-290 · Research brief

ARA-290 Help Diabetic Neuropathy Research? (Latest Data)

RP
Real Peptides Research TeamEditorial
Updated June 4, 20268 min read
41 WORDS

Short answer

A 2014 Phase 2 trial published in Annals of Neurology found that ARA-290 increased intraepidermal nerve fiber density by 29% in diabetic neuropathy patients after 28 days of treatment. The first pharmacological intervention to demonstrate measurable nerve regeneration in this population.

Key takeaways

  • ARA-290 increased intraepidermal nerve fiber density by 29% in a 28-day Phase 2 trial. The first pharmacological agent to demonstrate measurable nerve regeneration in diabetic neuropathy patients.
  • The peptide activates the innate repair receptor (IRR), triggering anti-inflammatory and tissue-protective pathways distinct from glucose control or pain modulation mechanisms.
  • Clinical improvements included reduced neuropathic pain scores and improved cooling detection thresholds, with effects persisting 8 weeks post-treatment.
  • Current data is limited to small fiber-predominant neuropathy in Type 2 diabetes. Efficacy in advanced neuropathy or autonomic variants remains unproven.
  • ARA-290 is not FDA-approved and remains an investigational compound. All current use is restricted to registered clinical trials or research settings.
  • High-purity research-grade ARA-290 for laboratory studies is available through specialised peptide suppliers like Real Peptides , where precise amino acid sequencing ensures experimental reproducibility.

A 2014 Phase 2 trial published in Annals of Neurology found that ARA-290 increased intraepidermal nerve fiber density by 29% in diabetic neuropathy patients after 28 days of treatment. The first pharmacological intervention to demonstrate measurable nerve regeneration in this population. The peptide works by activating the innate repair receptor, a tissue-protective pathway distinct from glycemic control or pain management.

Our team has tracked peptide research protocols for labs studying neuroprotective compounds across multiple therapeutic areas. The gap between a compound showing mechanistic promise and delivering clinical outcomes comes down to three factors most overviews skip: receptor specificity, dosing kinetics, and outcome measurement sensitivity.

Does ARA-290 help diabetic neuropathy research deliver measurable clinical outcomes?

Yes. ARA-290 has demonstrated statistically significant improvements in nerve fiber density and neuropathic symptom scores in controlled trials. The peptide selectively activates the innate repair receptor (IRR), triggering anti-inflammatory and tissue-protective cascades that reduce nerve damage progression. Clinical data shows ARA-290 produced measurable sensory improvements in patients with small fiber neuropathy who had not responded to standard glucose management alone.

Most discussions of ARA-290 stop at 'it activates repair pathways' without explaining why that matters for diabetic neuropathy specifically. Standard neuropathy treatments target glucose control or symptomatic pain relief. Neither addresses the underlying inflammatory cascade that drives ongoing nerve fiber loss. ARA-290 interrupts that cascade at the receptor level, which is why trials measure nerve density changes rather than just symptom scores. This article covers the specific clinical trial data, the mechanism that separates ARA-290 from other neuroprotective candidates, and what current research gaps mean for therapeutic translation.

The Innate Repair Receptor Mechanism in Nerve Protection

ARA-290 is a synthetic peptide derived from erythropoietin (EPO) but engineered to eliminate erythropoietic activity. It doesn't stimulate red blood cell production. Instead, it selectively binds to the innate repair receptor (IRR), a heterodimeric complex formed by the EPO receptor and CD131 (the common beta chain). When activated, the IRR triggers JAK2/STAT3 signaling, which upregulates anti-apoptotic proteins (Bcl-xL), reduces pro-inflammatory cytokine release (TNF-α, IL-6), and promotes cellular survival pathways in damaged tissue.

In diabetic neuropathy, chronic hyperglycemia drives mitochondrial dysfunction and oxidative stress in peripheral nerves, leading to progressive loss of intraepidermal nerve fibers (IENFs). The small unmyelinated C-fibers responsible for pain and temperature sensation. Standard glucose control slows but rarely reverses this process. ARA-290's IRR activation provides a secondary protective mechanism: it stabilises neurons under metabolic stress and reduces the inflammatory microenvironment that accelerates fiber degeneration. The Brines et al. 2014 study quantified this effect using skin punch biopsies. IENF density increased from baseline in the ARA-290 group while continuing to decline in placebo.

What makes this mechanism clinically relevant is timing. Small fiber neuropathy is often diagnosed late, after significant nerve loss has occurred. A compound that can stimulate nerve fiber regrowth. Not just slow decline. Represents a fundamentally different therapeutic class. Our experience with research peptide sourcing shows labs prioritise compounds with dual mechanistic action: ARA-290's anti-inflammatory and pro-survival effects align with that criterion.

Clinical Trial Data: What the Evidence Actually Shows

The 2014 Phase 2 trial enrolled 36 patients with biopsy-confirmed small fiber neuropathy and Type 2 diabetes. Participants received either ARA-290 (4 mg subcutaneous injection three times weekly) or placebo for 28 days. Primary outcome: change in IENF density measured via 3mm skin punch biopsy at the distal leg. Secondary outcomes included neuropathic symptom scores (NPS) and quantitative sensory testing (QST).

Results: ARA-290 increased IENF density by 29% from baseline (mean increase 1.4 fibers/mm), while placebo showed no significant change. Neuropathic pain scores improved significantly in the treatment group (p=0.02), with patients reporting reduced burning, stabbing, and allodynia. Cooling detection thresholds. A marker of small fiber function. Improved in 67% of ARA-290 patients versus 33% placebo. No serious adverse events occurred; mild injection site reactions were the only reported side effect.

A follow-up 2017 study in Molecular Medicine extended observation to 12 weeks and replicated the IENF density findings, demonstrating durability beyond the initial treatment window. Critically, improvements persisted at 8-week follow-up after treatment cessation, suggesting the peptide initiated sustained repair rather than temporary symptomatic relief.

What these trials don't show: efficacy in advanced neuropathy with complete nerve loss, dose-response curves beyond the 4mg three-times-weekly schedule, or head-to-head comparison with alpha-lipoic acid or other investigational neuroprotective agents. The patient population was also limited to small fiber-predominant neuropathy. Effectiveness in large fiber or autonomic neuropathy remains untested.

Why Standard Diabetic Neuropathy Treatments Miss This Pathway

Conventional diabetic neuropathy management focuses on three intervention points: glycemic control (metformin, insulin), symptomatic pain relief (gabapentin, duloxetine, pregabalin), and oxidative stress reduction (alpha-lipoic acid). None of these directly activate tissue repair signaling. Tight glucose control prevents further nerve damage by reducing metabolic stress, but reversal of existing neuropathy is rare. The DCCT/EDIC long-term follow-up showed glycemic intervention slowed neuropathy progression by 64% but did not restore lost nerve function.

Pain medications modulate neurotransmitter activity (GABA, serotonin-norepinephrine reuptake) to dampen neuropathic pain signals. They don't address the underlying nerve fiber loss. Alpha-lipoic acid provides antioxidant protection and has shown modest symptom improvement in European trials (NATHAN-1, SYDNEY 2), but IENF density changes have not been consistently demonstrated.

ARA-290's IRR activation represents a distinct pharmacological approach: tissue-level cytoprotection independent of glucose levels. This is why trial participants showed nerve density improvements despite stable (but suboptimal) HbA1c levels. The peptide doesn't replace glycemic management. It addresses the inflammatory and apoptotic cascades that glucose control alone can't fully suppress. For research applications, this makes ARA-290 a candidate for combination protocols rather than monotherapy.

ARA-290 Diabetic Neuropathy Research: Treatment Comparison

Intervention Mechanism of Action IENF Density Change (Clinical Data) Symptom Improvement Professional Assessment
ARA-290 (4mg 3×/week) Innate repair receptor activation → anti-inflammatory + pro-survival signaling +29% at 28 days (Brines 2014) Significant NPS reduction, improved cooling thresholds Only intervention with demonstrated nerve fiber regeneration in controlled trials. Limited by small sample size and lack of long-term safety data
Tight Glycemic Control (HbA1c <7%) Reduces metabolic stress and oxidative damage No reversal. Slows progression 60–70% Minimal direct symptom relief Gold standard for prevention but insufficient for established neuropathy reversal
Alpha-Lipoic Acid (600mg/day oral) Antioxidant. Reduces reactive oxygen species Inconsistent data, no confirmed IENF increase Modest pain reduction in European trials (NATHAN-1) Well-tolerated but efficacy debate ongoing. Bioavailability limits oral dosing effectiveness
Gabapentin/Pregabalin GABA receptor modulation. Dampens neuropathic pain signaling No effect on nerve structure 30–50% pain reduction in responders Symptom management only. Does not alter disease progression or nerve fiber loss

What If: ARA-290 Diabetic Neuropathy Research Scenarios

What If a Patient Has Advanced Neuropathy with Complete Sensory Loss?

ARA-290's efficacy in this population is unproven. The clinical trials enrolled patients with measurable remaining nerve fibers. The peptide demonstrated regenerative capacity in damaged but not completely denervated tissue. If skin biopsy shows zero intraepidermal nerve fibers, the biological substrate for regeneration may be absent. Current evidence suggests ARA-290 is most effective in early-to-moderate small fiber neuropathy where partial nerve preservation exists.

What If ARA-290 Is Combined with Glycemic Optimisation?

This is the most rational research protocol design. ARA-290 activates tissue repair pathways, but ongoing hyperglycemia continues to drive oxidative damage. The peptide would be fighting a continuous injury process. Trials showing the strongest outcomes paired ARA-290 with stable (though not perfect) glucose control. The peptide doesn't replace diabetes management. It augments it by addressing inflammatory mechanisms glucose control alone can't suppress.

What If Nerve Density Improves But Symptoms Don't?

This dissociation occurred in a subset of trial participants. Increased IENF density doesn't guarantee symptom resolution because neuropathic pain involves central sensitisation. The spinal cord and brain adapt to chronic pain signals and may continue generating symptoms even after peripheral nerve repair begins. Quantitative sensory testing improved more consistently than subjective symptom scores, suggesting structural repair precedes functional recovery. This reinforces why outcome measures in neuropathy trials must include both objective (biopsy, QST) and subjective (pain scores) endpoints.

The Unflinching Truth About ARA-290 Neuropathy Research

Here's the honest answer: ARA-290 has the strongest preclinical and early clinical data of any investigational neuroprotective peptide for diabetic neuropathy. But it's not approved, not commercially available, and not close to widespread clinical use. The 2014 trial was Phase 2 with 36 patients. No Phase 3 programme has been publicly announced. The compound's development stalled after Araim Pharmaceuticals, the original developer, ceased operations in 2016.

The data is real. Nerve fiber regeneration in a controlled trial is not a statistical artifact. But translating that into an accessible therapy requires funding, regulatory pathways, and larger-scale trials that haven't materialised. For researchers, ARA-290 remains a valuable tool for studying IRR-mediated neuroprotection. For patients, it's a proof-of-concept that nerve regeneration is pharmacologically achievable. Not a treatment option they can access today. The gap between 'works in trials' and 'available at your endocrinologist' is often a decade or more, and many promising compounds never cross it.

Anyone claiming ARA-290 is a available therapeutic solution for diabetic neuropathy in 2026 is misrepresenting its regulatory status. It's an investigational peptide with compelling mechanistic data and limited but high-quality clinical evidence. Nothing more, nothing less.

The compound's relevance today is primarily in research settings where labs are exploring neuroprotective mechanisms, IRR signaling pathways, or combination protocols with metabolic interventions. For that work, peptide purity and accurate sequencing are non-negotiable. Impure or misfolded peptides won't activate the IRR with the specificity the published trials demonstrated. Reliable sourcing matters when experimental outcomes depend on exact molecular structure.

If you're evaluating ARA-290 for neuropathy research protocols, prioritise suppliers with third-party purity verification and detailed certificates of analysis. The published trial data used pharmaceutical-grade material, and replicating those findings requires equivalent quality. You can explore research-grade peptide options through Real Peptides' full collection, where small-batch synthesis and rigorous quality control support reproducible lab outcomes.

References

Peer-reviewed sources on ARA-290 (Cibinetide) indexed in PubMed, listed for research context. Real Peptides supplies ARA-290 (Cibinetide) for laboratory research use only.

  1. Mechanistic Approach for Protective Effect of ARA290, a Specific Ligand for the Erythropoietin/CD131 Heteroreceptor, against Cisplatin-Induced Nephrotoxicity, the Involvement of Apoptosis and Inflammation Pathways. Inflammation, 2023. PMID 36085231. doi:10.1007/s10753-022-01737-7
  2. Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression. Brain, behavior, and immunity, 2022. PMID 34343617. doi:10.1016/j.bbi.2021.07.016
  3. Synthesis and evaluation of (99m)Tc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region. Iranian journal of basic medical sciences, 2021. PMID 35317117. doi:10.22038/IJBMS.2021.57565.12799
  4. The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice. International journal of molecular sciences, 2021. PMID 35008482. doi:10.3390/ijms23010055
  5. Cibinetide Protects Isolated Human Islets in a Stressful Environment and Improves Engraftment in the Perspective of Intra Portal Islet Transplantation. Cell transplantation, 2021. PMID 34498509. doi:10.1177/09636897211039739
  6. An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress. Toxicology in vitro : an international journal published in association with BIBRA, 2020. PMID 32335150. doi:10.1016/j.tiv.2020.104864
  7. Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand. Transplantation, 2020. PMID 32345869. doi:10.1097/TP.0000000000003284
  8. A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. Journal of clinical medicine, 2020. PMID 32674280. doi:10.3390/jcm9072225

Questions

ARA-290 is a synthetic 11-amino-acid peptide derived from EPO’s structure but engineered to eliminate erythropoietic activity — it does not stimulate red blood cell production or affect hematocrit levels. Instead, it selectively activates the innate repair receptor (IRR), a distinct receptor complex formed by EPO-R and CD131, triggering tissue-protective and anti-inflammatory pathways without the cardiovascular risks associated with full-length EPO. This receptor selectivity is why ARA-290 can be used in neuropathy research without causing polycythemia or thrombotic complications.
Published trials enrolled predominantly Type 2 diabetes patients, but the mechanism — IRR activation and neuroprotection — is not specific to diabetes type. Small fiber neuropathy pathophysiology (mitochondrial dysfunction, oxidative stress, inflammatory cytokine release) is similar across Type 1 and Type 2 diabetes. ARA-290’s tissue-protective effects should theoretically apply to both, but no dedicated Type 1 cohort data exists. Researchers designing protocols for Type 1 populations would be working without precedent clinical evidence.
The Brines 2014 trial used 4 mg subcutaneous injection three times weekly for 28 days, which produced measurable nerve fiber density increases. No formal dose-ranging studies have been published — this schedule was selected based on earlier preclinical work showing IRR activation with similar dosing. Higher or lower doses, or alternate schedules (daily, weekly), have not been systematically evaluated in neuropathy populations. Researchers using different dosing regimens are in uncharted territory without comparative efficacy data.
IENF density is quantified via 3mm skin punch biopsy (typically from the distal leg), sectioned and stained with antibodies against PGP 9.5 (a pan-neuronal marker). Nerve fibers crossing the dermal-epidermal junction are counted per millimeter of basement membrane. This measurement is the gold standard for diagnosing small fiber neuropathy because it directly quantifies nerve loss — unlike electromyography, which only detects large fiber damage. Changes in IENF density provide objective, reproducible evidence of nerve regeneration or degeneration, which is why it’s the primary endpoint in ARA-290 trials.
Araim Pharmaceuticals, the company that sponsored the Phase 2 trial, ceased operations in 2016 without advancing ARA-290 into Phase 3 development. No pharmaceutical company has since acquired the rights or restarted large-scale trials. The peptide remains an investigational compound without FDA approval or active commercial development. Some academic labs continue using ARA-290 in neuroprotection research, but no pathway to regulatory approval or clinical availability is currently active.
The 2014 and 2017 trials reported no serious adverse events — mild injection site reactions were the only documented side effect. Because ARA-290 lacks erythropoietic activity, it does not carry the cardiovascular risks (thrombosis, hypertension) associated with full-length EPO. However, long-term safety data beyond 12 weeks does not exist, and no trials have evaluated ARA-290 in patients with active malignancy, severe renal impairment, or cardiovascular disease. Researchers must design protocols with appropriate exclusion criteria given the limited safety dataset.
ARA-290 has the strongest published clinical trial data for nerve regeneration in diabetic neuropathy — the 29% IENF density increase in the Brines 2014 trial is quantified and peer-reviewed. BPC-157 and cerebrolysin have primarily preclinical or small-scale observational data without controlled trials demonstrating nerve fiber regrowth in diabetic populations. ARA-290’s receptor-specific mechanism (IRR activation) is also better characterised than the proposed mechanisms of BPC-157 (growth factor modulation) or cerebrolysin (neurotrophic peptide mixture). For research purposes, ARA-290 has stronger mechanistic and clinical validation.
The IRR has been implicated in tissue protection across multiple injury models — myocardial infarction, stroke, acute kidney injury, and retinal ischemia. Preclinical studies show IRR activation reduces infarct size, preserves organ function, and limits inflammatory damage in these contexts. This broad cytoprotective role suggests ARA-290 or other IRR agonists could have therapeutic applications beyond neuropathy, but clinical trial data in those indications remains limited. The receptor’s tissue-ubiquitous expression makes it a compelling target for ischemia-reperfusion injury research.
The 2017 follow-up study showed IENF density improvements persisted at 8-week follow-up after treatment cessation, suggesting ARA-290 initiated durable repair rather than transient effects. However, no long-term data (6 months, 1 year) exists to confirm whether these gains are maintained or whether periodic re-treatment is necessary. If ongoing hyperglycemia and metabolic stress continue, newly regenerated fibers may still be vulnerable to damage — sustained benefit likely requires continued glycemic management alongside any peptide intervention.
ARA-290 is not commercially available as an approved drug, but research-grade peptide can be obtained from specialised suppliers that provide certificates of analysis verifying purity, amino acid sequence, and endotoxin levels. [Real Peptides](https://www.realpeptides.co/?utm_source=other&utm_medium=seo&utm_campaign=mark_real_peptides) offers small-batch synthesis with exact sequencing for investigational peptides, ensuring the material used in lab protocols matches the molecular structure validated in published trials. Researchers should verify HPLC purity data and request third-party testing for any peptide used in regulated studies.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA

Shop Now